BioSpace News Archive

Amolyt Pharma, a global clinical-stage company specialized in developing therapeutic peptides for rare endocrine and metabolic diseases, today announced that the first subject in the Phase 1 clinical trial for AZP-3601 has been dosed.

Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics to reactivate mutant tumor suppressor protein, p53, today announced the launch of p53reactivation.com.

RAPT Therapeutics, Inc. (Nasdaq: RAPT), today announced the addition of preeminent oncology thought leaders, Lisa Butterfield, Ph.D. and Lawrence Fong, M.D., to its Scientific Advisory Board.

-- Is Oral Testosterone a Potential Treatment for COVID-19 in Men? -- TLANDO™, Oral Testosterone Replacement Therapy Without Dose Titration Requirement

NuVera Medical, Inc., a portfolio company of Shifamed LLC focused on enabling a new era in transcatheter cardiac interventions through the advancement of current 4D ICE imaging, today presented positive r

RayzeBio, Inc. announced today a $45M Series A financing to advance the development of its broad pipeline of targeted radiopharmaceuticals. Co-lead investors venBio Partners and Versant Ventures were joined by Sam

Large Study Demonstrates Exceptional Safety and High Procedural Success With Cardiovascular Systems’ Diamondback 360 ® Coronary Orbital Atherectomy System (OAS) ST. PAUL, Minn.--( BUSINESS WIRE )-- Cardiovascular Systems, Inc. (CSI ® ) (NASDAQ: CSII), a medical device company developing and commercializing innovative interventional treatment systems for patients with peripheral and coronary artery disease, announced today that results from a large retrosp

Baxter Supports New Study Showing Nutritional Needs in Critically Ill COVID-19 Patients and Published Practical Guidelines for Care Study is first to demonstrate importance of using indirect calorimetry (IC) to measure variable and dynamic energy needs of COVID-19 patients in the intensive care unit Data gathered from Q-NRG+ metabolic monitor device shows variance in resting energy expenditure (REE) measurements in comparison to frequently uti

TEPEZZA ® (teprotumumab-trbw) Data from the Phase 2 Clinical Trial Evaluate Longer-Term Responses in People Living with Thyroid Eye Disease (TED) -- New findings presented during the Academy of Managed Care Pharmacy Nexus 2020 Virtual Meeting showed most patients had at least some improvement in one or more disease parameters for up to one year following TEPEZZA treatment for TED, and are supported by recently announced long-term follow-up data from the Phas

Transparency Market Research has published a new report titled, ‘Testing and Analysis Services Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2019–2027’.